ARTICLE | Clinical News
FDA approves Keytruda in cervical cancer, PMBCL
June 15, 2018 7:30 PM UTC
Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy in patients whose tumors express PD-L1, with a Combined Positive Score (CPS) of ≥1 as determined by an FDA-approved test.
FDA approved Dako PD-L1 IHC 22C3 pharmDx assay from Agilent Technologies Inc. (NYSE:A) as a companion diagnostic to identify cervical cancer patients to be treated with Keytruda...
BCIQ Company Profiles
BCIQ Target Profiles